Inhibition of hepatitis B virus by a novel L-nucleoside, β-L-D4A and related analogues

World Journal of Gastroenterology

Volumn 9, Issue 8, 2003, Pages 1840-1843

  Wu, Jin Ming ^a,b   Lin, Ju Sheng ^a   Xie, Na ^a   Liang, Kuo Huan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIVIRUS AGENT; BETA LEVO 2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; DEXTRO 2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; DEXTRO 2',3' DIDEOXYADENOSINE; DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LEVO 2',3' DIDEOXYADENOSINE; LEVO NUCLEOSIDE; MACROGOL; MITOCHONDRIAL DNA; PHOSPHORUS 32; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; AUTORADIOGRAPHY; CALCULATION; CELL STRAIN HEPG2; CULTURE MEDIUM; CYTOTOXICITY; DENSITOMETRY; DIGESTION; DNA EXTRACTION; DNA HYBRIDIZATION; DNA PROBE; DRUG EFFECT; GENOME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; NONHUMAN; SOUTHERN BLOTTING; STRUCTURE ACTIVITY RELATION; TISSUE CULTURE CELL; VIRION; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0042427791     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i8.1840     Document Type: Article

References (22)

1. Bridges EG, Cheng YC. Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Prog Liver Dis 1995; 13: 231-245
2. Freiman JS, Mc Caughan GW. Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings. J Gastroenterol Hepatol 2000; 15: 227-229
3. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley-Usmar VM. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 2000; 44: 496-503
4. Van Draanen NA, Tisdale M, Parry NR, Jansen R, Dornsife RE, Tuttle JV, Averett DR, Koszalka GW. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother 1994; 38: 868-871
5. Zoulim F. Therapy of chronic hepatitis B virus infection: Inhibition of the viral polymerase and other antiviral strategies. Antiviral Res 1999; 44: 1-30
6. Lai CL, Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol 2000; 61: 367-373
7. Hawkins AE, Zuckerman MA, Briggs M, Gilson RJ, Goldstone AH, Brink NS, Tedder RS. Hepatitis B nucleotide sequence analysis: Linking an outbreak of acute hepatitis B to contamination of a cryopreservation tank. J Virol Methods 1996; 60: 81-88
8. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, Bowsher RR, Richardson FC, Lewis W, Cote PJ, Korba BE, Gerin JL. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998; 28: 179-191
9. Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, Gerin JL, Cote PJ, Tennant BC, Cheng YC. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998;3 (Suppl 3): 113-121
10. Colacino JM. Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Antiviral Res 1996; 29: 125-139
11. Lin JS, Kira T, Gullen E, Choi Y, Qu F, Chu CK, Cheng YC. Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. J Med Chem 1999; 42: 2212-2217
12. Ma T, Pai SB, Zhu YL, Lin JS, Shanmuganathan K, Du J, Wang C, Kim H, Newton MG, Cheng YC, Chu CK. Structure-activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl) pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996; 39: 2835-2843
13. Kotra LP, Xiang Y, Newton MG, Schinazi RF, Cheng YC, Chu CK. Structure-activity relationships of 2′-deoxy-2′, 2′-difluoro-L-erythro-pentofuranosyl nucleosides. J Med Chem 1997; 40: 3635-3644
14. Qiu YL, Ptak RG, Breitenbach JM, Lin JS, Cheng YC, Kern ER, Drach JC, Zemlicka J. (Z)- and (E)-2-(hydroxymethylcyclopropylidene)-methylpurines and pyrimidines as antiviral agents. Antivir Chem Chemother 1998; 9: 341-352
15. Qiu YL, Ksebati MB, Ptak RG, Fan BY, Breitenbach JM, Lin JS, Cheng YC, Kern ER, Drach JC, Zemlicka J. (Z)- and (E)-2-((hydroxymethyl) cyclopropylidene) methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity. J Med Chem 1998; 41: 10-23
16. Du J, Surzhykov S, Lin JS, Newton MG, Cheng YC, Schinazi RF, Chu CK. Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. J Med Chem 1997; 40: 2991-2993
17. Lu X, Gong S, Monks A, Zaharevitz D, Moscow JA. Correlation of nucleoside and nucleobase transporter gene expression with anti-metabolite drug cytotoxicity. J Exp Ther Oncol 2002; 2: 200-212
18. Hostetler KY, Korba BE, Sridhar CN, Gardner MF. Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. Antiviral Res 1994; 24: 59-67
19. Gudmundsson KS, Tidwell J, Lippa N, Koszalka GW, Van Draanen N, Ptak RG, Drach JC, Townsend LB. Synthesis and antiviral evaluation of halogenated beta-D- and -L-erythrofuranosylbenzimidazoles. J Med Chem 2000; 43: 2464-2472
20. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001; 81: 1537-1544
21. Leung N. Liver disease-significant improvement with lamivudine. J Med Virol 2000; 61: 380-385
22. Deschamps D, Flandre P, Joly V, Meiffredy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastere S, Aboulker JP, Yeni P, Brun-Vezinet F. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. J Acquir Immune Defic Syndr 2002; 31: 464-471